Greenbrook TMS NeuroHealth Centers, North America’s largest provider of Transcranial Magnetic Stimulation (TMS Therapy) to patients suffering with depression, is pleased to announce it has reached a major milestone having provided more than 100,000 treatments to patients. TMS Therapy is an FDA-cleared and proven medical treatment for patients diagnosed with Major Depressive Disorder (MDD) who are resistant to antidepressant medication.
“We are excited to cross this very significant milestone,” said Bill Leonard, Greenbrook’s CEO & President. “The outstanding clinical results we have been experiencing mean that thousands of patients are now able to return to living fulfilling, productive and happy lives.”
Greenbrook TMS NeuroHealth Centers operates a fast-growing network of treatment centers in partnership with community physicians. Greenbrook TMS currently operates 27 centers throughout Maryland, Virginia, the Washington DC Metro Area, North Carolina and Delaware and will reach 30 locations by the end of the year.
“TMS is a breakthrough therapy that has changed the paradigm of how we approach the treatment of depression,” said Chief Medical Officer, Geoffrey Grammer, M.D. “At Greenbrook we pride ourselves on our quality of care and providing an exceptional patient experience.”
TMS is an FDA-cleared, non-drug, non-sedating, non-invasive medical treatment for patients suffering with depression without any of the typical side effects experienced with antidepressant medications, such as weight gain, fatigue, and sexual dysfunction. TMS can be used as a stand-alone treatment or in conjunction with medication. TMS uses magnetic pulses to stimulate areas of the brain known to control mood which have been scientifically identified as underactive in people who suffer with depression. A typical treatment course is 36 sessions, typically administered 5 days a week for 4-6 weeks when depression is in its acute phase.